Core Viewpoint - The stock of HAPO (02142) has seen a significant increase following the announcement of a substantial share purchase by the Government of Singapore Investment Corporation (GIC) and the release of strong interim financial results [1] Group 1: Share Purchase - GIC increased its stake in HAPO by acquiring 40.22 million ordinary shares at an average price of HKD 12.7133 per share, totaling approximately HKD 511 million [1] - Post-acquisition, GIC's total shareholding in HAPO rose to 53.977 million shares, increasing its ownership percentage from 1.62% to 6.37% [1] Group 2: Financial Performance - HAPO reported interim revenue of approximately USD 101 million, representing a year-on-year increase of about 327% [1] - The company's profit for the period was USD 72.999 million, showing a year-on-year growth of 5,125% [1] Group 3: Fundraising and Use of Proceeds - HAPO plans to place a total of 45.02 million new shares, accounting for 5.17% of the enlarged share capital, at a placement price of HKD 11.5 per share, expecting to raise net proceeds of approximately HKD 512 million [1] - Approximately 50% of the proceeds will be allocated to the research and development of innovative drug assets, around 40% will support clinical trials for existing pipeline drug assets, and about 10% will be used for working capital and other general corporate purposes [1]
港股异动 | 和铂医药-B(02142)高开近5% GIC斥资超5亿港元增持公司股份 持股比例突破6%